Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 8/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.35 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14814904 | 0.90 | GPBAR1 (0.43) | GPBAR1CYP3A4CYP2C19LMNATP53 | |
| SCHEMBL14814884 | 0.83 | GPBAR1 (0.44) | GPBAR1CYP3A4CYP2C19LMNATP53 | |
| SCHEMBL14814566 | 0.73 | DHODH (0.51) | GPBAR1CYP3A4CYP2C19LMNADHODH | |
| SCHEMBL14830237 | 0.70 | DHODH (0.49) | GPBAR1CYP3A4CYP2C19LMNADHODH | |
| SCHEMBL11006800 | 0.66 | SMN1; SMN2 (0.53) | GPBAR1CYP3A4CYP2C19TP53MAPT | |
| SCHEMBL14814993 | 0.66 | DHODH (0.47) | GPBAR1CYP3A4CYP2C19LMNAMAPT | |
| SCHEMBL14833280 | 0.65 | DHODH (0.45) | GPBAR1CYP3A4CYP2C19LMNAMAPT | |
| SCHEMBL14815046 | 0.64 | POLB (0.40) | CYP3A4LMNAMAPTHPGDBRD4 | |
| SCHEMBL30407844 | 0.63 | L3MBTL1 (0.52) | GPBAR1CYP3A4CYP2C19LMNAMAPT | |
| SCHEMBL10940226 | 0.62 | SMN1; SMN2 (0.48) | GPBAR1CYP3A4CYP2C19HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013049585-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | HENGRUI (USA), LTD. (US) | 2013-04-04 | — | — | WO | claimed |
| US-20130085157-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | SMITH EMILIE D (US) | 2013-04-04 | — | — | US | claimed |
| US-20130085157-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | SMITH EMILIE D (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085157-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | SMITH EMILIE D (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085157-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | SMITH EMILIE D (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049585-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | HENGRUI (USA), LTD. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085157-A1 | ARYLSUBSTITUTED THIAZOLOTRIAZOLES AND THIAZOLOIMIDAZOLES | TGM2, CCT5, TSHR | GPBAR1 42/4885CYP3A4 1878/4885CYP2C19 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.